181 related articles for article (PubMed ID: 29869464)
21. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Analytical and Clinical Performance of HPV 9G DNA Chip, PANArray HPV Genotyping Chip, and Hybrid-Capture II Assay in Cervicovaginal Swabs.
Jung HY; Han HS; Kim HB; Oh SY; Lee SJ; Kim WY
J Pathol Transl Med; 2016 Mar; 50(2):138-46. PubMed ID: 26763506
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Xpert
Rabaan AA; Taylor DR; Dawamneh MF; Al-Tawfiq JA
J Infect Public Health; 2017; 10(2):219-223. PubMed ID: 27343005
[TBL] [Abstract][Full Text] [Related]
27. Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection.
Ko K; Kwon MJ; Lee EH; Woo HY; Park H
J Clin Lab Anal; 2017 Mar; 31(2):. PubMed ID: 27387091
[TBL] [Abstract][Full Text] [Related]
28. Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities.
Fornari D; Rebolj M; Bjerregård B; Lidang M; Christensen I; Høgdall E; Bonde J
Cytopathology; 2016 Aug; 27(4):249-60. PubMed ID: 26990233
[TBL] [Abstract][Full Text] [Related]
29. Punch biopsy guided by both colposcopy and HR-HPV status is more efficient for identification of immediate high-grade squamous intraepithelial lesion or worse among HPV-infected women with atypical squamous cells of undetermined significance.
Ding Z; Li Y; Chen A; Song M; Zhang Y
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():32-36. PubMed ID: 27816739
[TBL] [Abstract][Full Text] [Related]
30. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real time PCR and the PCR-reverse dot blot assays.
Zhang L; Dai Y; Chen J; Hong L; Liu Y; Ke Q; Chen Y; Cai C; Liu X; Chen Z
J Med Virol; 2018 Jan; 90(1):177-183. PubMed ID: 28851089
[TBL] [Abstract][Full Text] [Related]
32. HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data.
Martins TR; Mendes de Oliveira C; Rosa LR; de Campos Centrone C; Rodrigues CL; Villa LL; Levi JE
Virol J; 2016 Aug; 13():138. PubMed ID: 27515763
[TBL] [Abstract][Full Text] [Related]
33. [HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].
Burroni E; Sani C; Bisanzi S; Ocello C
Epidemiol Prev; 2016; 40(3-4):164-70. PubMed ID: 27436249
[TBL] [Abstract][Full Text] [Related]
34. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the digene HPV genotyping LQ test and the PANArray HPV genotyping chip for detection of high-risk or probable high-risk human papillomavirus genotypes.
Park KS; Kim JY; Ki CS; Lee NY
Ann Lab Med; 2014 Jul; 34(4):279-85. PubMed ID: 24982832
[TBL] [Abstract][Full Text] [Related]
36. High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand.
Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Intaraphet S; Siriaunkgul S
J Med Virol; 2016 Jan; 88(1):135-43. PubMed ID: 26129775
[TBL] [Abstract][Full Text] [Related]
37. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
38. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus genotype specificity of hybrid capture 2.
Castle PE; Solomon D; Wheeler CM; Gravitt PE; Wacholder S; Schiffman M
J Clin Microbiol; 2008 Aug; 46(8):2595-604. PubMed ID: 18579716
[TBL] [Abstract][Full Text] [Related]
40. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
